Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
6 Solid Vehicle Fix Administrations to Keep Your Vehicle in Prime Condition - 2Find the Effect of Web-based Entertainment on Psychological wellness: Exploring the Advanced Scene Securely
- 3Most loved Seared Chicken: Which Chain Rules?
- 4IDF finds weapon of slain hostage Capt. Daniel Perez in booby-trapped Gaza compound
- 54 injured in shooting at North Carolina tree lighting ceremony
- French lawmakers narrowly approve health care budget, suspending Macron's flagship pension reform
- One spent $20 on candy. Another paid $700 for a custom costume. Here's how Halloween costs stacked up this year.
- Nature's Treats: 10 Organic products That Lift Prosperity
- As reefs vanish, assisted coral fertilization offers hope in the Dominican Republic
- Regeneron's experimental therapy combo effective in untreated cancer patients
- ISS astronauts spy airglow and dwarf galaxy | Space photo of the day for Jan. 13, 2026
- What to watch for in weight loss drugs in 2026
- MacArthur Foundation awards $100M to outbreak surveillance network, a boost amid global health cuts
- 4 Coolers for Present day Kitchens
